Impact BioMedical Inc.
New York Stock Exchange AmericanCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Frank D. Heuszel
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1400 Broadfield Blvd. Houston TX United States of America 77084
- IPO Date
- Sep 16, 2024
- CIK
- 0001834105
- Website
- impactbiomedinc.com
- Similar Companies
- Business
- Impact BioMedical Inc. (NYSE American: IBO), a biotechnology company headquartered in Houston, Texas and founded in 2018, discovers, develops and commercializes innovative products and technologies addressing unmet needs in human healthcare and wellness, with a focus on specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare and wellness offerings primarily in the United States. The company offers its proprietary Linebacker platform of small molecule electrophilically enhanced polyphenol compounds for applications in oncology, inflammatory disorders and neurology; Laetose technology, a unique sugar-inositol combination that inhibits inflammatory and metabolic responses associated with sugar consumption; functional fragrance formulations incorporating specialized botanical ingredients such as terpenes serving as antimicrobials and additives for insect repellents, detergents, lotions, shampoos and fabrics; Equivir/Equivir G, a GRAS-eligible polyphenol blend demonstrating antiviral effects for health supplements and medications; and Celios air purification technology for improving indoor air quality through patented filtration solutions. In June 2025, Impact BioMedical entered into a definitive merger agreement with Dr Ashleys Limited, a Hong Kong-based global pharmaceutical company specializing in active pharmaceutical ingredients and orphan drugs, under which Dr Ashleys will acquire Impact BioMedical through a reverse merger resulting in a combined NYSE American-listed entity operated by Dr Ashleys management; the transaction, unanimously approved by both boards, awaits shareholder approval, SEC registration effectiveness and NYSE listing approval to accelerate commercialization of Impact BioMedical's 90-plus patent portfolio leveraging Dr Ashleys' global infrastructure and financial resources. Previously a wholly owned subsidiary of DSS Inc., Impact BioMedical completed its initial public offering in September 2024, with certain shares from a prior DSS dividend subject to trading restrictions ending in March 2025.
Impact Biomedical Investor News: Rosen Law Firm Encourages Impact Biomedical Inc. Investors to Inquire About Securities Class Action Investigation – IBO
Rosen Law Firm Encourages Impact Biomedical Inc. Investors to Inquire About Securities Class Action Investigation – IBO
Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans
Impact Biomedical Inc (IBO) Announces 3F™ US Patent Issue
IBO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Impact BioMedical Inc. Is Fair to Shareholders
Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger
Impact Biomedical Inc. Announcement Stock Activity/Pricing
Impact BioMedical Inc. to Present at The Microcap Conference
Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker™ Technology Targeting Inflammatory Disease
Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates
Impact BioMedical Inc. (NYSE: IBO) Announces 3F™ US Patent Issue
Impact BioMedical Inc. Announces the Closing of its Initial Public Offering
Impact BioMedical Inc. Announces Pricing of Initial Public Offering